Highbridge Capital Management’s Meridian Bioscience Inc VIVO Stock Holding History

Highbridge Capital Management’s Portfolio VIVO Stock Details VIVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-22,723	Closed	-$323K	–	1420
2018 Q1	$323K	Buy	+22,723	New	+$336K	0.01%	844
2017 Q4	–	Sell	-15,594	Closed	-$223K	–	2059
2017 Q3	$223K	Buy	+15,594	New	+$223K	﹤0.01%	1369
2017 Q2	–	Sell	-92,683	Closed	-$1.28M	–	1707
2017 Q1	$1.28M	Buy	+92,683	New	+$1.3M	0.02%	543
2016 Q3	–	Sell	-18,331	Closed	-$358K	–	1762
2016 Q2	$358K	Buy	+18,331	New	+$359K	0.01%	984
2015 Q2	–	Sell	-21,864	Closed	-$417K	–	1736
2015 Q1	$417K	Buy	+21,864	New	+$404K	0.01%	1018

Other funds holding VIVO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SFM

Systematic Financial Management Teaneck, New Jersey $4.36B AUM 40.56% 1-Year Est. Return

Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Highbridge Capital Management's VIVO Position: Q2 2018 in Review

Highbridge Capital Management sold out of Meridian Bioscience Inc (VIVO) in Q2 2018, closing a stake of 22,723 shares — an estimated $323K sold.

Highbridge Capital Management first reported a position in VIVO in Q1 2015 and held it in 5 quarters. The position peaked at $1.28M in Q1 2017. 177 funds tracked by Wall St. Rank hold VIVO as of Q2 2018.

Highbridge Capital Management reported no remaining Meridian Bioscience Inc position as of Q2 2018 after selling out during the quarter.
Highbridge Capital Management sold 22,723 Meridian Bioscience Inc shares in Q2 2018, an estimated $323K.
Highbridge Capital Management first reported a position in Meridian Bioscience Inc in Q1 2015 and held it in 5 quarters.
Highbridge Capital Management's Meridian Bioscience Inc position peaked at $1.28M in Q1 2017.
177 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q2 2018.

Based on Highbridge Capital Management's 13F filing for Q2 2018, filed 14 Aug 2018.